CEEGOG z.s.

Gynecologic Oncology

The clinical research activity is centered on early-stage cervical cancer, with a particular focus on intermediate-risk disease after radical surgery. The main therapeutic interest lies in postoperative management and the role of adjuvant therapy in this setting.

  • Cervical cancer
  • Early-stage disease
  • Intermediate-risk patients
  • Post-surgical treatment

Research activity in this area is linked to international collaboration across multiple sites in Europe and other participating countries.

Postoperative Cancer Management

The sponsor’s trial portfolio examines treatment decisions after surgery, with attention to whether additional therapy improves outcomes compared with observation alone. The clinical interest is in reducing recurrence risk and preserving disease-free survival in patients with surgically treated cervical cancer.

  • Adjuvant treatment
  • Disease-free survival
  • Recurrence prevention
  • Observation versus further treatment

The research setting includes coordinated participation from a broad network of collaborating sites supporting oncologic follow-up.

Multicentre Oncology Collaboration

The sponsor is involved in multicentre clinical research spanning several countries, reflecting interest in harmonised care for patients with gynecologic malignancies. The study environment supports shared evaluation of treatment strategies across diverse clinical settings.

  • International collaboration
  • Multinational site network
  • Gynecologic malignancies
  • Clinical coordination

The active trial network involves participating research sites in multiple countries, with the sponsor based in Prague, Czechia.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effects of Carboplatin and Cisplatin in Patients with Early-Stage, Intermediate-Risk Cervical Cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Italy Poland Spain